Eagle Asset Management Inc. Has $13.53 Million Stake in Masimo (MASI)

Eagle Asset Management Inc. lifted its stake in Masimo (NASDAQ:MASI) by 356.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 153,875 shares of the medical equipment provider’s stock after purchasing an additional 120,171 shares during the period. Eagle Asset Management Inc. owned approximately 0.30% of Masimo worth $13,533,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Intrust Bank NA lifted its stake in shares of Masimo by 15.5% in the first quarter. Intrust Bank NA now owns 4,490 shares of the medical equipment provider’s stock valued at $395,000 after purchasing an additional 603 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Masimo by 7.4% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 10,368 shares of the medical equipment provider’s stock valued at $879,000 after purchasing an additional 718 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Masimo by 39.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,820 shares of the medical equipment provider’s stock valued at $239,000 after purchasing an additional 802 shares during the period. Brown Capital Management LLC lifted its stake in shares of Masimo by 0.8% in the fourth quarter. Brown Capital Management LLC now owns 98,506 shares of the medical equipment provider’s stock valued at $8,353,000 after purchasing an additional 819 shares during the period. Finally, OppenheimerFunds Inc. lifted its stake in shares of Masimo by 36.6% in the fourth quarter. OppenheimerFunds Inc. now owns 4,505 shares of the medical equipment provider’s stock valued at $382,000 after purchasing an additional 1,206 shares during the period. Hedge funds and other institutional investors own 82.92% of the company’s stock.

Shares of Masimo opened at $98.49 on Thursday, according to MarketBeat. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 40.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.95. Masimo has a 12-month low of $80.69 and a 12-month high of $100.00.



Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.06. The company had revenue of $212.90 million during the quarter, compared to analysts’ expectations of $205.65 million. Masimo had a return on equity of 23.14% and a net margin of 15.99%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business earned $0.57 earnings per share. equities analysts expect that Masimo will post 2.88 EPS for the current year.

In related news, EVP Yongsam Lee sold 4,100 shares of Masimo stock in a transaction dated Tuesday, April 24th. The stock was sold at an average price of $90.13, for a total value of $369,533.00. Following the completion of the transaction, the executive vice president now directly owns 72,200 shares of the company’s stock, valued at $6,507,386. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ramshorst David J. Van sold 3,000 shares of Masimo stock in a transaction dated Friday, May 4th. The shares were sold at an average price of $97.50, for a total value of $292,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 2,500 shares of the company’s stock, valued at $243,750. The disclosure for this sale can be found here. Over the last three months, insiders have sold 122,303 shares of company stock valued at $11,148,690. Company insiders own 12.60% of the company’s stock.

Several brokerages recently commented on MASI. ValuEngine upgraded shares of Masimo from a “hold” rating to a “buy” rating in a research note on Monday, May 7th. BidaskClub upgraded shares of Masimo from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 8th. Zacks Investment Research cut shares of Masimo from a “buy” rating to a “hold” rating in a research note on Monday, May 7th. BTIG Research reiterated a “buy” rating and issued a $100.00 price objective on shares of Masimo in a research note on Thursday, May 3rd. Finally, Piper Jaffray Companies raised their price objective on shares of Masimo to $94.00 and gave the company a “neutral” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $101.17.

Masimo Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply